What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

To evaluate the efficacy of an AAV-delivered activated FIX Padua variant in treating hemophilia B.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Gene therapy enhances hemostatic efficiency in hemophilia B, suggesting potential for better patient outcomes.

To evaluate the efficacy of an AAV-delivered activated FIX Padua variant in treating hemophilia B.
Developed a gene therapy cassette encoding activated human FIX Padua variant
Transfected HEK293 cells to assess FIX activity
Administered AAV8 vector to hemophilia B mice and a canine model
Used saphenous vein bleeding assay and thromboelastography to evaluate hemostatic efficacy
Activated FIX Padua variant showed robust hemostatic correction in animal models
Significant improvement in clotting events in hemophilia B mice
TEG R-time reduced significantly in a hemophilia B dog after treatment

Nichols et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark